Enanta announces AbbVie report of MAVYRET data at AASLD.
Enanta Pharmaceuticals (ENTA) announced the presentation of new data for AbbVie's (ABBV) pan-genotypic chronic hepatitis C virus treatment, MAVYRET, in treatment-naive patients with compensated cirrhosis. Results from AbbVie's Phase 3b EXPEDITION-8 study showed that with 8 weeks of MAVYRET, 100% of genotype 1, 2, 4, 5 and 6 patients achieved a sustained virologic response 12 weeks after treatment per protocol analysis. To date, no virologic failures have been reported in cohort one of the study and no patients have discontinued treatment due to adverse events. These data are being presented today as a late-breaking, oral presentation at The Liver Meeting 2018 organized by the American Association for the Study of Liver Diseases, or AASLD. MAVYRET is a pan-genotypic, once-daily, ribavirin-free treatment that combines glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, dosed once-daily as three oral tablets, taken with food. Glecaprevir was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals for HCV protease inhibitors and regimens that include protease inhibitors.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Nov 13, 2018|
|Previous Article:||Galmed trial data on Aramchol 600mg presented at the Liver Meeting.|
|Next Article:||Zendesk launches Sunshine, 'an open and flexible CRM platform'.|